Cargando…
Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective
Epigenetic remodeling and metabolic reprogramming, two well-known cancer hallmarks, are highly intertwined. In addition to their abilities to confer cancer cell growth advantage, these alterations play a critical role in dynamically shaping the tumor microenvironment and antitumor immunity. Recent s...
Autores principales: | Lebedev, Timofey, Kousar, Rubina, Patrick, Bbumba, Usama, Muhammad, Lee, Meng-Kuei, Tan, Ming, Li, Xing-Guo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047504/ https://www.ncbi.nlm.nih.gov/pubmed/36980292 http://dx.doi.org/10.3390/cells12060952 |
Ejemplares similares
-
Carbon Nanomaterials: Emerging Roles in Immuno-Oncology
por: Patrick, Bbumba, et al.
Publicado: (2023) -
What nature has to offer: Opportunities for immuno-oncology
por: Kousar, Rubina, et al.
Publicado: (2023) -
Targeting the Metabolic Vulnerability of ARID1A-Deficient Hepatocellular Carcinoma
por: Chan, For-Fan, et al.
Publicado: (2022) -
Targeting HSPA1A in ARID2-deficient lung adenocarcinoma
por: Wang, Xue, et al.
Publicado: (2021) -
ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
por: Zhang, Le, et al.
Publicado: (2023)